Actively Recruiting
Randomized Study of Pembrolizumab and Platinum Chemotherapy With or Without Zoldonrasib for First-Line Treatment of Metastatic Non-Squamous RAS G12D-Mutated Non-Small Cell Lung Cancer
Led by Revolution Medicines, Inc. · Updated on 2026-11-04
430
Participants Needed
4
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an investigational RASON inhibitor called zoldonrasib, combined with pembrolizumab and platinum-based chemotherapy, compared to placebo plus pembrolizumab and platinum-based chemotherapy. This Phase 3, global, randomized, double-blind study focuses on patients with previously untreated, first-line metastatic RAS G12D-mutated non-squamous non-small cell lung cancer NSCLC. The goal is to see if adding zoldonrasib improves progression-free survival. Participants will be assigned to one of two study groups one receiving zoldonrasib oral tablets together with pembrolizumab given by IV infusion or subcutaneous injection and a platinum-based chemotherapy doublet pemetrexed plus either cisplatin or carboplatin IV infusions, and the other receiving placebo oral tablets with the same pembrolizumab and chemotherapy combination. Treatments are given in cycles of 21 days. During the study, participants will undergo various assessments including tumor measurements, laboratory tests for organ function, and quality of life questionnaires. Researchers will monitor progression-free survival over approximately five years, along with overall survival, response rates, adverse events, vital signs, and symptom changes. Regular visits will include drug concentration checks and safety evaluations to understand the impact of the treatments.
CONDITIONS
Brief Title
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Research Team
R
Revolution Medicines Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here